Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03026257 · ClinicalTrials.gov registry record · NA

Clinical Assessment of a HYDRAGLYDE® Regimen

A NA study of Myopia and Refractive Errors, sponsored by Alcon, a Novartis Company.

Completed
Registry status
NA
Development phase
323
Enrollment target
8
Study locations

NCT03026257 is a NA study of Myopia and Refractive Errors that has completed, run by Alcon, a Novartis Company. The registered enrollment target is 323 participants, above the 264-participant average among 90 other Myopia trials with a reported enrollment target (22% higher). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03026257, a NA study of Myopia and Refractive Errors, has completed, sponsored by Alcon, a Novartis Company.

COMPLETED
Registry status
NA
Development phase
323 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual multi-purpose solution (MPS) for cholesterol uptake.

Conditions Studied

Myopia Refractive Errors Hypermetropia

Interventions

  • DEVICE Lotrafilcon B contact lenses with added wetting agent
  • DEVICE Samfilcon A contact lenses
  • DEVICE POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent
  • DEVICE Hydrogen peroxide-based contact lens solution with added wetting agent
  • DEVICE Senofilcon C contact lenses

Study Locations (8)

Ohio

  • Alcon Investigative Site - Cleveland
  • Alcon Investigative Site - Columbus

Other

  • Alcon Investigative Site - Hildesheim
  • Alcon Investigative Site - Jena

Alabama

  • Alcon Investigative Site - Birmingham

Tennessee

  • Alcon Investigative Site - Memphis

Texas

  • Alcon Investigative Site - Houston

Ontario

  • Alcon Investigative Site - Waterloo

Trial Details

FieldValue
Enrollment Target 323 participants
Start Date 2017-02-13
Est. Completion 2017-08-18
Phase NA

Sponsor

Alcon, a Novartis Company

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03026257

The ClinicalTrials.gov registry entry for NCT03026257 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 264-participant average among 90 other Myopia trials with a reported enrollment target (22% higher). The listed sponsor is Alcon, a Novartis Company, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 5 interventions - of which Lotrafilcon B contact lenses with added wetting agent is the first listed.

NCT03026257 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Ohio, Other, Alabama.

Frequently Asked Questions

What is clinical trial NCT03026257 about?

NCT03026257 is a clinical study titled "Clinical Assessment of a HYDRAGLYDE® Regimen". The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual multi-purpose solution (MPS) for c...

What is the current status of trial NCT03026257?

This trial is currently completed. It is a NA study. The enrollment target is 323 participants. The study started on 2017-02-13. Estimated completion is 2017-08-18.

What conditions does trial NCT03026257 study?

This clinical trial studies the following conditions: Myopia, Refractive Errors, Hypermetropia.

What interventions are being tested in trial NCT03026257?

The interventions under investigation include: Lotrafilcon B contact lenses with added wetting agent (DEVICE), Samfilcon A contact lenses (DEVICE), POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent (DEVICE), Hydrogen peroxide-based contact lens solution with added wetting agent (DEVICE), Senofilcon C contact lenses (DEVICE).

Who is sponsoring clinical trial NCT03026257?

This trial is sponsored by Alcon, a Novartis Company, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03026257 being conducted?

This trial has 8 study locations across Alabama, Ohio, Tennessee, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myopia

All registered trials for this condition

Refractive Errors

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.